Moreover, Wang et al. reported that serum VEGF is a biomarker that correlates with neoadjuvant chemotherapy response in triple-negative breast cancer, including the predictive value of pathological complete response to neoadjuvant chemotherapy and DFS [22]. Here, VEGFA is linked to triple-negative breast carcinoma.